Caxton Associates (New York)’s ADMA Biologics ADMA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $884K | Sell |
51,568
-24,280
| -32% | -$416K | 0.03% | 236 |
|
|
2024
Q3 | $1.52M | Sell |
75,848
-130,879
| -63% | -$2.62M | 0.06% | 173 |
|
|
2024
Q2 | $2.31M | Sell |
206,727
-182,464
| -47% | -$2.04M | 0.08% | 133 |
|
|
2024
Q1 | $2.57M | Buy |
389,191
+369,498
| +1,876% | +$2.44M | 0.14% | 95 |
|
|
2023
Q4 | $89K | Buy |
+19,693
| New | +$89K | ﹤0.01% | 447 |
|
|
2023
Q3 | – | Sell |
-140,190
| Closed | -$517K | – | 389 |
|
|
2023
Q2 | $517K | Sell |
140,190
-64,729
| -32% | -$239K | 0.08% | 264 |
|
|
2023
Q1 | $678K | Sell |
204,919
-30,256
| -13% | -$100K | 0.1% | 207 |
|
|
2022
Q4 | $912K | Buy |
+235,175
| New | +$912K | 0.06% | 114 |
|